A detailed history of American International Group, Inc. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, American International Group, Inc. holds 71,794 shares of NUVB stock, worth $213,946. This represents 0.0% of its overall portfolio holdings.

Number of Shares
71,794
Previous 72,411 0.85%
Holding current value
$213,946
Previous $109,000 139.45%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$1.46 - $3.97 $900 - $2,449
-617 Reduced 0.85%
71,794 $261,000
Q4 2023

Feb 13, 2024

SELL
$0.96 - $1.53 $280 - $446
-292 Reduced 0.4%
72,411 $109,000
Q3 2023

Nov 13, 2023

BUY
$1.26 - $2.1 $3,257 - $5,428
2,585 Added 3.69%
72,703 $97,000
Q2 2023

Aug 04, 2023

BUY
$1.56 - $1.84 $21,747 - $25,651
13,941 Added 24.82%
70,118 $126,000
Q1 2023

May 12, 2023

BUY
$1.6 - $2.48 $1,788 - $2,772
1,118 Added 2.03%
56,177 $93,000
Q4 2022

Feb 10, 2023

SELL
$1.68 - $2.5 $336 - $500
-200 Reduced 0.36%
55,059 $105,000
Q3 2022

Nov 14, 2022

BUY
$0.29 - $4.04 $226 - $3,155
781 Added 1.43%
55,259 $124,000
Q2 2022

Aug 12, 2022

SELL
$3.24 - $5.85 $79,201 - $143,003
-24,445 Reduced 30.97%
54,478 $177,000
Q1 2022

May 13, 2022

SELL
$4.6 - $8.83 $25,552 - $49,050
-5,555 Reduced 6.58%
78,923 $415,000
Q4 2021

Feb 11, 2022

BUY
$7.75 - $10.05 $371,690 - $481,998
47,960 Added 131.33%
84,478 $718,000
Q3 2021

Nov 12, 2021

BUY
$7.78 - $10.0 $129,692 - $166,700
16,670 Added 83.99%
36,518 $363,000
Q2 2021

Aug 13, 2021

BUY
$9.22 - $14.48 $182,998 - $287,399
19,848 New
19,848 $185,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $647M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.